Jessica D. Faul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica D. Faul has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer A. Smith
Department of Epidemiology, School of Public Health, University of Michigan
42 shared publications Wei Zhao
Survey Research Center, Institute for Social Research, University of Michigan
26 shared publicationsDavid R. Weir
Survey Research Center, Institute for Social Research, University of Michigan
18 shared publications- Albert Vernon Smith
University of Michigan
17 shared publications Albert Hofman
Department of Epidemiology, Erasmus University Medical center, Rotterdam
15 shared publications- Erin Bakshis Ware
University of Michigan
14 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
Epigenetic g predicts cognitive function in a diverse, nationally representative sample of older adults
Alzheimer's disease and related dementias (ADRD) are major public health concerns. DNA methylation (DNAm)-based biomarkers such as GrimAge and PhenoAge predict aging and health risk, but were not designed to optimize prediction of cognitive function or decline. Epigenetic g-a DNAm-derived index of general cognitive ability-is a promising marker of cognitive function that has not been assessed in a racially and socioeconomically diverse population. We used data from the 2016 Venous Blood Study of the Health and Retirement Study (HRS), a nationally representative cohort of U.S. adults aged ≥ 51 years (N = 3575 with high-quality DNAm). Epigenetic g scores were computed using CpG weights from a BayesR+ model of general cognitive ability developed in Generation Scotland. Cognitive function was measured with a modified version of the Telephone Interview for Cognitive Status (TICS) at each interview wave. Linear regression estimated associations with cognitive scores; mixed-effect growth curve models estimated the association with cognitive change. Models were adjusted sequentially for demographics, education, parental education, APOE ε4 status, and blood-based neurodegeneration markers (NfL, GFAP, Aβ42/40, pTau181). Higher epigenetic g was associated with better baseline cognition (β = 2.55, 95% CI 1.80-3.30)) and cognition at the time DNAm was measured (β = 2.30, 95% CI 1.47-3.13) after demographic adjustment. Associations were attenuated but remained significant with education and parental education (β = 1.23-1.89). In growth curve models, Epigenetic g was associated with higher cognitive performance but did not have a statistically significant association with decline over a 6-year period. Results were robust to adjustment for APOE ε4 and neurodegeneration biomarkers. Epigenetic g is a scalable, blood-based marker of cognitive function, and potentially or cognitive reserve, that adds predictive value beyond demographics, socioeconomic indicators, APOE, and neuropathology. Its validation in a diverse, nationally representative U.S. cohort underscores its potential for early risk profiling and for research on social determinants of cognitive aging in cross-national samples.
- 2 May 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
Open AccessEpigenetic g predicts cognitive function in a diverse, nationally representative sample of older adults
Alzheimer's disease and related dementias (ADRD) are major public health concerns. DNA methylation (DNAm)-based biomarkers such as GrimAge and PhenoAge predict aging and health risk, but were not designed to optimize prediction of cognitive function or decline. Epigenetic g-a DNAm-derived index of general cognitive ability-is a promising marker of cognitive function that has not been assessed in a racially and socioeconomically diverse population. We used data from the 2016 Venous Blood Study of the Health and Retirement Study (HRS), a nationally representative cohort of U.S. adults aged ≥ 51 years (N = 3575 with high-quality DNAm). Epigenetic g scores were computed using CpG weights from a BayesR+ model of general cognitive ability developed in Generation Scotland. Cognitive function was measured with a modified version of the Telephone Interview for Cognitive Status (TICS) at each interview wave. Linear regression estimated associations with cognitive scores; mixed-effect growth curve models estimated the association with cognitive change. Models were adjusted sequentially for demographics, education, parental education, APOE ε4 status, and blood-based neurodegeneration markers (NfL, GFAP, Aβ42/40, pTau181). Higher epigenetic g was associated with better baseline cognition (β = 2.55, 95% CI 1.80-3.30)) and cognition at the time DNAm was measured (β = 2.30, 95% CI 1.47-3.13) after demographic adjustment. Associations were attenuated but remained significant with education and parental education (β = 1.23-1.89). In growth curve models, Epigenetic g was associated with higher cognitive performance but did not have a statistically significant association with decline over a 6-year period. Results were robust to adjustment for APOE ε4 and neurodegeneration biomarkers. Epigenetic g is a scalable, blood-based marker of cognitive function, and potentially or cognitive reserve, that adds predictive value beyond demographics, socioeconomic indicators, APOE, and neuropathology. Its validation in a diverse, nationally representative U.S. cohort underscores its potential for early risk profiling and for research on social determinants of cognitive aging in cross-national samples.
- 6 February 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 187, 107779
Association between allostatic load and incident dementia, and race/ethnic disparities in the association in the U.S. health and retirement study
- 6 February 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 187, 107779
Association between allostatic load and incident dementia, and race/ethnic disparities in the association in the U.S. health and retirement study
- Open Access
The association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adults
INTRODUCTION: The association of blood-based biomarkers of neuropathology with cognition, dementia, and mortality and how these association potentially differ by race/ethnicity, has not been examined in large, diverse, nationally-representative samples of adults. METHODS: The sample included Health and Retirement Study (HRS) respondents over age 50 with blood-based neuropathology biomarker, demographic, and cognitive data (n=4,214). A β -40, A β -42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured in plasma (Quanterix Neurology 4-Plex E kit), and phosphorylated tau (pTau-181) was measured in serum (Quanterix Advantage V2.0 kit). Cognitive tests included immediate and delayed word recall, serial 7s, and backward counting (total score 0-27). Dementia classification relied on a diagnostic algorithm previously validated in the HRS. RESULTS: When each biomarker was analyzed individually, higher A β -42/A β -40 ratio was associated with better cognitive function among non-Hispanic (NH) whites. Higher NfL was associated with worse cognitive function in the total sample and in each race/ethnic group (NH white, NH black, and Hispanic). Higher pTau-181 was associated with worse cognitive function in the total and NH white sample. Higher GFAP was related to worse cognitive function in the total sample only. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group, and irrespective of APOE status. NfL was predictive of 6-year incident dementia in our sample (OR=1.33). All four markers significantly predicted 6-year mortality. DISCUSSION: In a large nationally-representative sample of US adults, we found that NfL was the most consistent predictor of cross-sectional and incident dementia 6 years post blood collection. NfL was also the most consistent predictor across race/ethnic groups examined in our study. Highlights: There are currently limited data on blood-based biomarkers of neuropathology as predictors of cognitive performance and incident dementia in diverse, population-based cohort studies. We used data from the Health and Retirement Study (n-=4,214) to examine the association between blood-based biomarkers of neuropathology and cognitive function, as well as their association with incident dementia and mortality 4 years after measurement. Mean levels of A β -42/A β -40 were similar across race/ethnic groups and age groups in this US population-representative sample where selection effects have been minimized. Average NfL was higher among non-Hispanic blacks and Hispanics; GFAP was higher among non-Hispanic blacks as compared to non-Hispanic whites. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group. NfL was associated with incident dementia 6 years after measurement in the total sample. A β -42/A β -40 ratio was predictive of 6-year incident dementia among those with at least one APOE e4 allele.
Open AccessThe association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adults
INTRODUCTION: The association of blood-based biomarkers of neuropathology with cognition, dementia, and mortality and how these association potentially differ by race/ethnicity, has not been examined in large, diverse, nationally-representative samples of adults. METHODS: The sample included Health and Retirement Study (HRS) respondents over age 50 with blood-based neuropathology biomarker, demographic, and cognitive data (n=4,214). A β -40, A β -42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured in plasma (Quanterix Neurology 4-Plex E kit), and phosphorylated tau (pTau-181) was measured in serum (Quanterix Advantage V2.0 kit). Cognitive tests included immediate and delayed word recall, serial 7s, and backward counting (total score 0-27). Dementia classification relied on a diagnostic algorithm previously validated in the HRS. RESULTS: When each biomarker was analyzed individually, higher A β -42/A β -40 ratio was associated with better cognitive function among non-Hispanic (NH) whites. Higher NfL was associated with worse cognitive function in the total sample and in each race/ethnic group (NH white, NH black, and Hispanic). Higher pTau-181 was associated with worse cognitive function in the total and NH white sample. Higher GFAP was related to worse cognitive function in the total sample only. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group, and irrespective of APOE status. NfL was predictive of 6-year incident dementia in our sample (OR=1.33). All four markers significantly predicted 6-year mortality. DISCUSSION: In a large nationally-representative sample of US adults, we found that NfL was the most consistent predictor of cross-sectional and incident dementia 6 years post blood collection. NfL was also the most consistent predictor across race/ethnic groups examined in our study. Highlights: There are currently limited data on blood-based biomarkers of neuropathology as predictors of cognitive performance and incident dementia in diverse, population-based cohort studies. We used data from the Health and Retirement Study (n-=4,214) to examine the association between blood-based biomarkers of neuropathology and cognitive function, as well as their association with incident dementia and mortality 4 years after measurement. Mean levels of A β -42/A β -40 were similar across race/ethnic groups and age groups in this US population-representative sample where selection effects have been minimized. Average NfL was higher among non-Hispanic blacks and Hispanics; GFAP was higher among non-Hispanic blacks as compared to non-Hispanic whites. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group. NfL was associated with incident dementia 6 years after measurement in the total sample. A β -42/A β -40 ratio was predictive of 6-year incident dementia among those with at least one APOE e4 allele.
- Open Access
Epigenetic g predicts cognitive aging and incident dementia in a diverse, nationally representative sample of older adults
Background: Alzheimer’s disease and related dementias (ADRD) are major public health concerns. DNA methylation (DNAm)–based biomarkers such as GrimAge and PhenoAge predict aging and health risk, but were not designed to optimize prediction of cognitive decline. Epigenetic g —a DNAm-derived index of general cognitive ability—is a promising marker of cognitive function that has not been assessed in a racially and socioeconomically diverse population. Methods: We used data from the 2016 Venous Blood Study of the Health and Retirement Study (HRS), a nationally representative cohort of U.S. adults aged ≥51 years (N = 3575 with high-quality DNAm). Epigenetic g scores were computed using CpG weights from a BayesR+ model of general cognitive ability developed in Generation Scotland. Cognitive function was measured with a modified version of the Telephone Interview for Cognitive Status (TICS) at each interview wave; 6-year incident dementia was defined using the validated Langa–Weir algorithm. Linear regression estimated associations with cognitive scores; logistic regression estimated 4-year dementia risk. Models were adjusted sequentially for demographics, education, parental education, APOE ε4 status, and blood-based neurodegeneration markers (NfL, GFAP, Aβ42/40, pTau181). Results: Higher epigenetic g was associated with better baseline cognition (β=2.55, 95% CI 1.92–3.17) and cognition at the time DNAm was measured (β=2.30, 95% CI 1.62–2.99) after demographic adjustment. Associations attenuated but remained significant with education and parental education (β=1.23–1.89). Each unit increase in epigenetic g predicted 29% lower 6-year risk of dementia (fully adjusted HR=0.71). Results were robust to adjustment for APOE ε4 and neurodegeneration biomarkers. Conclusions: Epigenetic g is a scalable, blood-based marker of cognitive function and dementia risk that adds predictive value beyond demographics, socioeconomic indicators, APOE, and neuropathology. Its validation in a diverse, nationally representative U.S. cohort underscores its potential for early risk profiling and for research on social determinants of cognitive aging in cross-national samples.
Open AccessEpigenetic g predicts cognitive aging and incident dementia in a diverse, nationally representative sample of older adults
Background: Alzheimer’s disease and related dementias (ADRD) are major public health concerns. DNA methylation (DNAm)–based biomarkers such as GrimAge and PhenoAge predict aging and health risk, but were not designed to optimize prediction of cognitive decline. Epigenetic g —a DNAm-derived index of general cognitive ability—is a promising marker of cognitive function that has not been assessed in a racially and socioeconomically diverse population. Methods: We used data from the 2016 Venous Blood Study of the Health and Retirement Study (HRS), a nationally representative cohort of U.S. adults aged ≥51 years (N = 3575 with high-quality DNAm). Epigenetic g scores were computed using CpG weights from a BayesR+ model of general cognitive ability developed in Generation Scotland. Cognitive function was measured with a modified version of the Telephone Interview for Cognitive Status (TICS) at each interview wave; 6-year incident dementia was defined using the validated Langa–Weir algorithm. Linear regression estimated associations with cognitive scores; logistic regression estimated 4-year dementia risk. Models were adjusted sequentially for demographics, education, parental education, APOE ε4 status, and blood-based neurodegeneration markers (NfL, GFAP, Aβ42/40, pTau181). Results: Higher epigenetic g was associated with better baseline cognition (β=2.55, 95% CI 1.92–3.17) and cognition at the time DNAm was measured (β=2.30, 95% CI 1.62–2.99) after demographic adjustment. Associations attenuated but remained significant with education and parental education (β=1.23–1.89). Each unit increase in epigenetic g predicted 29% lower 6-year risk of dementia (fully adjusted HR=0.71). Results were robust to adjustment for APOE ε4 and neurodegeneration biomarkers. Conclusions: Epigenetic g is a scalable, blood-based marker of cognitive function and dementia risk that adds predictive value beyond demographics, socioeconomic indicators, APOE, and neuropathology. Its validation in a diverse, nationally representative U.S. cohort underscores its potential for early risk profiling and for research on social determinants of cognitive aging in cross-national samples.
- Open Access
- 30 December 2025
- Published by Springer Nature in Research Square
Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: Unraveling the interplay with risk of dementia
Background and Objectives: Impaired lung function (ILF) has been associated with cognitive decline and dementia risk in multiple cohorts, yet the role of circulating Alzheimer disease (AD) biomarkers in this relationship is not well understood. We aim to assess the associations between ILF and AD biomarkers and to determine whether these biomarkers mediate the relationship between ILF and incident dementia. Methods: Serum p-Tau181 and plasma Aβ42/40, NfL, and GFAP were measured in 4,072 participants (mean age 66 ± 10; 59% women) in the 2016 Health and Retirement Study. Peak Expiratory Flow (PEF) was assessed in 2012/2014, and cognitive function was measured at four time points between 2014 and 2020 (every two years) to determine dementia status. Impaired lung function (ILF) was defined as predicted PEF <80%. Multivariable regression examined associations between lung function and AD biomarkers; causal mediation analysis evaluated their role in linking lung function to incident dementia. Results: In total, 881 (21.6%) participants had ILF and 272 (6.8%) participants developed dementia. After adjusting for demographics, education, BMI, smoking, comorbidities, inflammation, eGFR and APOE e4 , ILF was associated with a higher risk of dementia (HR=1.74; 95% CI (1.34, 225)). Individuals with ILF had 0.10 SD higher NfL (SE= 0.03; p= 0.004) and 0.09 SD higher p-Tau 181 (SE= 0.03; p= 0.002) compared to those without ILF. NfL mediated 7.3% (p=0.01) of the total effect of ILF on dementia, while p-Tau 181 mediated 5% (p=0.05) of this association. Discussion: ILF was associated with elevated levels of neurodegeneration markers NfL and p-Tau 181, which partially mediated its relationship with dementia risk. These findings highlight the importance of monitoring blood protein biomarkers in individuals with impaired lung health to facilitate early interventions.
- 30 December 2025
- Published by Springer Nature in Research Square
Open AccessImpaired lung function is associated with elevated blood biomarkers of AD/ADRD: Unraveling the interplay with risk of dementia
Background and Objectives: Impaired lung function (ILF) has been associated with cognitive decline and dementia risk in multiple cohorts, yet the role of circulating Alzheimer disease (AD) biomarkers in this relationship is not well understood. We aim to assess the associations between ILF and AD biomarkers and to determine whether these biomarkers mediate the relationship between ILF and incident dementia. Methods: Serum p-Tau181 and plasma Aβ42/40, NfL, and GFAP were measured in 4,072 participants (mean age 66 ± 10; 59% women) in the 2016 Health and Retirement Study. Peak Expiratory Flow (PEF) was assessed in 2012/2014, and cognitive function was measured at four time points between 2014 and 2020 (every two years) to determine dementia status. Impaired lung function (ILF) was defined as predicted PEF <80%. Multivariable regression examined associations between lung function and AD biomarkers; causal mediation analysis evaluated their role in linking lung function to incident dementia. Results: In total, 881 (21.6%) participants had ILF and 272 (6.8%) participants developed dementia. After adjusting for demographics, education, BMI, smoking, comorbidities, inflammation, eGFR and APOE e4 , ILF was associated with a higher risk of dementia (HR=1.74; 95% CI (1.34, 225)). Individuals with ILF had 0.10 SD higher NfL (SE= 0.03; p= 0.004) and 0.09 SD higher p-Tau 181 (SE= 0.03; p= 0.002) compared to those without ILF. NfL mediated 7.3% (p=0.01) of the total effect of ILF on dementia, while p-Tau 181 mediated 5% (p=0.05) of this association. Discussion: ILF was associated with elevated levels of neurodegeneration markers NfL and p-Tau 181, which partially mediated its relationship with dementia risk. These findings highlight the importance of monitoring blood protein biomarkers in individuals with impaired lung health to facilitate early interventions.
- Open Access
Large-Scale Gene-Smoking Interactions and Fine Mapping Study Identifies Multiple Novel Blood Pressure Loci in over 1 Million Individuals
Cigarette smoking influences blood pressure (BP) levels. Studying and accounting for potential gene-smoking interactions can help discover novel loci and provide insights into biological pathways for smoking-associated BP regulation. We conducted a genome-wide association meta-analysis involving 1,188,241 individuals from 66 studies in five ancestry groups, analyzing systolic BP, diastolic BP, and pulse pressure while considering interactions between genetic variants and three smoking exposures: smoking status, cigarettes per day, and pack years. These analyses identified twelve novel loci for BP at genome-wide significance ( P < 5 × 10 −9 ), and highlighted biological processes including tight junction integrity, mitochondrial health, vascular relaxation, and endothelial function. In smoking status-stratified analyses, smoking modifies the genetic effect of six variants on BP. To prioritize likely causal, we developed and applied SuSiEgxe, a fine-mapping method based on a two-degree-of-freedom joint test using gene-environment interaction summary statistics. Fine-mapped loci uncovered immune-related pathway for smoking-associated BP regulation.
Open AccessLarge-Scale Gene-Smoking Interactions and Fine Mapping Study Identifies Multiple Novel Blood Pressure Loci in over 1 Million Individuals
Cigarette smoking influences blood pressure (BP) levels. Studying and accounting for potential gene-smoking interactions can help discover novel loci and provide insights into biological pathways for smoking-associated BP regulation. We conducted a genome-wide association meta-analysis involving 1,188,241 individuals from 66 studies in five ancestry groups, analyzing systolic BP, diastolic BP, and pulse pressure while considering interactions between genetic variants and three smoking exposures: smoking status, cigarettes per day, and pack years. These analyses identified twelve novel loci for BP at genome-wide significance ( P < 5 × 10 −9 ), and highlighted biological processes including tight junction integrity, mitochondrial health, vascular relaxation, and endothelial function. In smoking status-stratified analyses, smoking modifies the genetic effect of six variants on BP. To prioritize likely causal, we developed and applied SuSiEgxe, a fine-mapping method based on a two-degree-of-freedom joint test using gene-environment interaction summary statistics. Fine-mapped loci uncovered immune-related pathway for smoking-associated BP regulation.
- 24 September 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (12)
A novel DNA methylation-based surrogate biomarker for chronic systemic inflammation (Inflammation Latent Variable Methylation Surrogate, InfLaMeS)
Chronic low-grade systemic inflammation is a risk factor for chronic diseases and mortality and is an important biomarker in health research. DNA methylation (DNAm) surrogate biomarkers are valuable exposure, risk factor, and health outcome predictors in studies where the measures cannot be measured directly and often perform as well or better than direct measures. We generated a DNAm surrogate biomarker for chronic, systemic inflammation from a systemic inflammation latent variable of 7 inflammatory markers and evaluated its performance relative to measured inflammatory biomarkers in predicting several age-associated outcomes of interest, including mortality, activities of daily living, and multimorbidity in the Health and Retirement Study (HRS). The DNAm surrogate, Inflammation Latent Variable Methylation Surrogate (InfLaMeS), correlated with 7 individual inflammation markers (r = −0.2-0.6) and had similar or stronger associations with multimorbidity, disability, and 4-year mortality in HRS compared to the systemic inflammation latent variable measure when predicting multimorbidity, disability, and 4-year mortality in HRS. Findings were validated in an external cohort, the Irish Longitudinal Study of Ageing. These results suggest that InfLaMeS provides a robust alternative to measured blood-chemistry measures of inflammation with broad research applicability in instances where values of inflammatory markers are not measured but DNAm data are available.
- 24 September 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (12)
A novel DNA methylation-based surrogate biomarker for chronic systemic inflammation (Inflammation Latent Variable Methylation Surrogate, InfLaMeS)
Chronic low-grade systemic inflammation is a risk factor for chronic diseases and mortality and is an important biomarker in health research. DNA methylation (DNAm) surrogate biomarkers are valuable exposure, risk factor, and health outcome predictors in studies where the measures cannot be measured directly and often perform as well or better than direct measures. We generated a DNAm surrogate biomarker for chronic, systemic inflammation from a systemic inflammation latent variable of 7 inflammatory markers and evaluated its performance relative to measured inflammatory biomarkers in predicting several age-associated outcomes of interest, including mortality, activities of daily living, and multimorbidity in the Health and Retirement Study (HRS). The DNAm surrogate, Inflammation Latent Variable Methylation Surrogate (InfLaMeS), correlated with 7 individual inflammation markers (r = −0.2-0.6) and had similar or stronger associations with multimorbidity, disability, and 4-year mortality in HRS compared to the systemic inflammation latent variable measure when predicting multimorbidity, disability, and 4-year mortality in HRS. Findings were validated in an external cohort, the Irish Longitudinal Study of Ageing. These results suggest that InfLaMeS provides a robust alternative to measured blood-chemistry measures of inflammation with broad research applicability in instances where values of inflammatory markers are not measured but DNAm data are available.
- Open Access
- 21 August 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (12) , 3705-3713
Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers—the ratio of Amyloid beta 42-40 (Aβ42/Aβ40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)—in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher Aβ42/Aβ40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the Aβ42/Aβ40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging. This article is part of a Special Collection on Cross-National Gerontology.
- 21 August 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (12) , 3705-3713
Open AccessAssociation of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers—the ratio of Amyloid beta 42-40 (Aβ42/Aβ40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)—in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher Aβ42/Aβ40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the Aβ42/Aβ40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging. This article is part of a Special Collection on Cross-National Gerontology.
- Open Access
- 29 July 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (9)
Dynamics of multimorbidity, health expectancy, and survival in middle aged and older individuals
Background: Life expectancy has increased, but such increase has disproportionally expanded the period of life with diseases. Whether expanding health expectancy (HE), defined as years of life free of chronic diseases, could also affect rate of multimorbidity accumulation is uncertain. Objective: to investigate the dynamic relationship between HE and rate of multimorbidity accumulation and their impact on survival. Methods: Four thousand two hundred seventy-four (3511 > 50 years) participants from the Health and Retirement Study (HRS), healthy at baseline and developing at least one disease overtime were included. Mean baseline age was 55.1 years and average follow-up was 9.4 years. Multimorbidity was operationalized as count of diagnosed diseases from a list of nine chronic conditions. HE was operationalized as years from birth until when the first disease was ascertained, and percentage of life in good health calculated as percentage of life lived free of chronic diseases. Mixed models investigated the association between HE and rate of multimorbidity accumulation, while survival analyses evaluated association with time to death. Results: HE were positively associated with multimorbidity rate (P < .001). Shorter HE and faster multimorbidity rate were independently associated with higher mortality (P < .001). Their interaction was negatively associated with mortality (P < .001). Results were confirmed restricting the analysis to individuals 51 or older and using HRS specific weights. Individuals with longer HE experienced a greater survival, almost regardless of multimorbidity rate, while a positive gradient was found in percentage of life in good health linked to multimorbidity rate. Conclusions: Expanding health expectancy is likely followed by compression of morbidity.
- 29 July 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (9)
Open AccessDynamics of multimorbidity, health expectancy, and survival in middle aged and older individuals
Background: Life expectancy has increased, but such increase has disproportionally expanded the period of life with diseases. Whether expanding health expectancy (HE), defined as years of life free of chronic diseases, could also affect rate of multimorbidity accumulation is uncertain. Objective: to investigate the dynamic relationship between HE and rate of multimorbidity accumulation and their impact on survival. Methods: Four thousand two hundred seventy-four (3511 > 50 years) participants from the Health and Retirement Study (HRS), healthy at baseline and developing at least one disease overtime were included. Mean baseline age was 55.1 years and average follow-up was 9.4 years. Multimorbidity was operationalized as count of diagnosed diseases from a list of nine chronic conditions. HE was operationalized as years from birth until when the first disease was ascertained, and percentage of life in good health calculated as percentage of life lived free of chronic diseases. Mixed models investigated the association between HE and rate of multimorbidity accumulation, while survival analyses evaluated association with time to death. Results: HE were positively associated with multimorbidity rate (P < .001). Shorter HE and faster multimorbidity rate were independently associated with higher mortality (P < .001). Their interaction was negatively associated with mortality (P < .001). Results were confirmed restricting the analysis to individuals 51 or older and using HRS specific weights. Individuals with longer HE experienced a greater survival, almost regardless of multimorbidity rate, while a positive gradient was found in percentage of life in good health linked to multimorbidity rate. Conclusions: Expanding health expectancy is likely followed by compression of morbidity.
- 5 May 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (1) , 54-68
How much can biomarkers explain sociodemographic inequalities in cognitive dysfunction and cognitive impairment? Results from a machine learning model in the Health and Retirement Study
Background: Biomarkers may be pathways by which social adversity affects cognitive aging and Alzheimer's disease and related dementias (ADRD) risk. Objective: How much variance in cognitive dysfunction and cognitive impairment onset do blood-based and physiological biomarkers provide above and beyond easily attainable sociodemographic variables, and how much can biomarkers explain differences in cognitive functioning and ADRD by sociodemographic variables? Methods: We utilize machine learning to generate measures of predicted cognitive dysfunction and cognitive impairment incidence based on 91 biomarkers, identify the relative importance of each biomarker, and examine how much these biomarkers mediate sociodemographic differences. Results: Markers related to cellular aging, neurodegeneration, diet and nutrition, immune functioning, and lung function were identified as important. Biomarkers mediated 47.2–77.3% of the variance associated with age, 22.7–35.2% of racial/ethnic differences in cognitive dysfunction, and 12.5–17.6% of educational differences. Conclusions: Biomarkers provide the potential to understand pathways linking sociodemographic characteristics to cognitive functioning and health. Future research should consider additional biomarkers and evaluate the specific systems that put people at risk for cognitive impairment.
- 5 May 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (1) , 54-68
How much can biomarkers explain sociodemographic inequalities in cognitive dysfunction and cognitive impairment? Results from a machine learning model in the Health and Retirement Study
Background: Biomarkers may be pathways by which social adversity affects cognitive aging and Alzheimer's disease and related dementias (ADRD) risk. Objective: How much variance in cognitive dysfunction and cognitive impairment onset do blood-based and physiological biomarkers provide above and beyond easily attainable sociodemographic variables, and how much can biomarkers explain differences in cognitive functioning and ADRD by sociodemographic variables? Methods: We utilize machine learning to generate measures of predicted cognitive dysfunction and cognitive impairment incidence based on 91 biomarkers, identify the relative importance of each biomarker, and examine how much these biomarkers mediate sociodemographic differences. Results: Markers related to cellular aging, neurodegeneration, diet and nutrition, immune functioning, and lung function were identified as important. Biomarkers mediated 47.2–77.3% of the variance associated with age, 22.7–35.2% of racial/ethnic differences in cognitive dysfunction, and 12.5–17.6% of educational differences. Conclusions: Biomarkers provide the potential to understand pathways linking sociodemographic characteristics to cognitive functioning and health. Future research should consider additional biomarkers and evaluate the specific systems that put people at risk for cognitive impairment.